Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality

Jennifer R. Stark, Fredrik Wiklund, Henrik Grönberg, Fredrick Schumacher, Jennifer A. Sinnott, Meir J. Stampfer, Lorelei A. Mucci and Peter Kraft
Jennifer R. Stark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredrik Wiklund
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Grönberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredrick Schumacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Sinnott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meir J. Stampfer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorelei A. Mucci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Kraft
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-08-0981 Published June 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Additional Files
  • Table 1.

    Demographic and tumor characteristics of the 1,252 CaPS cases (2001-2002)

    Characteristic
    Age at diagnosis, median (range), y65.9 (47.3-80.4)
    Years of follow-up, median (range)5.1 (0.4-6.5)
    Family history, n (%)
        None1088 (86.9)
        1 blood relative118 (9.4)
        ≥2 blood relatives46 (3.7)
    T stage, n (%)
        T1428 (34.2)
        T2377 (30.1)
        T3239 (19.1)
        T4/N1/M1176 (14.0)
        Missing32 (2.6)
    Gleason, n (%)
        2-5182 (14.5)
        6405 (32.4)
        7338 (27.0)
        8-10192 (15.3)
        Missing135 (10.8)
    Curative treatment,* n (%)602 (48.1)
    Hormonal therapy,† n (%)577 (46.1)
    • ↵* Curative treatment includes radical prostatectomy or radiation.

    • ↵† Includes medical and surgical hormone therapy.

  • Table 2.

    Distribution of SNPs and likelihood ratio test P values from Cox proportional hazards models of prostate cancer mortality among 1,252 cases

    Geners numberLocationVariationMinor allele frequencyLRT P value*
    Multivariate model 1†Multivariate model 2‡
    COX-2rs2745557202C>T0.170.930.89
    rs52756,365T>C0.350.240.48
    rs46482763,935T>C0.110.910.97
    rs6894708,365C>T0.030.790.97
    rs204323,100T>G0.140.760.94
    IL-1RNrs8789722,118A>C0.260.480.78
    rs3159348,111T>C0.190.980.99
    rs308726310,173G>A0.090.960.70
    rs31595114,992C>G0.330.090.09
    IL-6rs14743481,027G>C0.490.700.78
    rs20698453,268G>A0.480.150.29
    rs1800795−237G>C0.490.440.79
    rs1800796−636G>C0.040.800.64
    rs1800797−661G>A0.490.620.89
    IL-10rs1800871−853C>T0.260.660.46
    rs1800872−627C>A0.270.660.46
    rs30245092,483T>C0.070.890.94
    rs30245055,876C>T0.120.660.29
    rs1800896−1,117A>G0.460.800.83
    rs15542861,547C>T0.220.780.55
    IRAK1rs10597021,071 (F196S)C>T0.120.860.79
    rs70617894,788T>C0.180.980.99
    rs10597036,434 (S532L)T>C0.130.800.87
    rs30278789,373T>G0.180.990.99
    IRAK4rs1057190−13,656T>C0.110.360.40
    rs4251431−7,225G>T0.090.700.92
    rs4251571−2,001A>G0.020.430.15
    rs4251459652T>C0.110.360.44
    rs42514877,987G>C0.020.580.44
    rs425154518,380 (A428G)G>A0.100.710.87
    rs425155920,791A>G0.440.660.58
    MIC-1rs1058587Exon2 +2,423C>G0.280.950.99
    rs1059519Exon1 +25C>G0.290.140.53
    rs1059369Exon1 +142A>T0.270.300.41
    rs1227732IVS1 +1,809G>T0.160.002§0.009
    MyD88rs4988453−938C>A0.060.390.19
    TIRAPrs6460059,537T>C0.370.710.79
    rs817737614,115T>G0.240.960.80
    rs1229046817,678G>A0.050.710.99
    TLR1rs5743551−7,202A>G0.230.020.03
    rs5743556−6,399T>C0.150.210.35
    N/A−2,299T>C0.180.820.98
    rs5743604−833T>C0.300.040.06
    rs5743611238G>C0.110.980.89
    rs46246632,576A>G0.040.960.99
    TLR2rs3804099596T>C0.430.580.61
    rs38041001,349T>C0.060.260.38
    TLR3rs3775296−7C>A0.180.780.94
    rs57433132,593C>T0.180.820.92
    rs37752916,301C>T0.300.920.44
    rs5743303−8,921A>T0.170.750.94
    rs57433058,441T>A0.330.800.80
    TLR4rs11536889−11,380G>C0.120.840.74
    rs10759932−1,607T>C0.150.990.86
    rs2149356IVS3−468G>T0.300.640.56
    rs49867908,551A>G0.050.870.99
    rs1927914−2,026A>G0.330.720.88
    rs107599333,622A>C0.050.990.96
    rs50307219,615G>A0.010.940.86
    rs115368713,748A>C0.020.920.97
    rs787378412,185G>C0.140.960.97
    rs1153689117,050T>C0.140.860.99
    TLR5n/a−27,694C>T0.480.390.17
    rs2241096−23,799C>T0.120.980.92
    rs20724931,774A>G0.150.990.94
    rs57441741,845T>C0.480.730.56
    rs10539542,533A>G0.080.750.71
    TLR6rs5743788−2,113C>G0.500.090.16
    rs5743795−1,401G>A0.180.160.31
    rs5743806−673G>C0.320.090.11
    rs5743810744C>T0.400.170.30
    rs57438151,279T>C0.020.710.93
    TLR7rs2302267−120T>G0.060.780.87
    rs1790194,271C>A0.230.990.95
    rs1790168,744G>C0.410.320.58
    rs162023312,381C>T0.100.100.20
    rs17900817,961A>T0.250.950.84
    TLR8rs1548731−558C>T0.260.620.99
    rs48308063,467C>T0.390.840.55
    rs57440686,553C>T0.160.830.97
    rs57440809,299C>T0.360.990.99
    rs574408812,059G>C0.160.830.98
    TLR9rs187084−1,486T>C0.440.009∥0.05
    TLR10rs11466617−3,260T>C0.160.120.12
    rs11466640−1,692C>T0.170.270.41
    rs4274855−260G>A0.170.320.52
    rs11096957720 (N241H)A>C0.370.040.06
    rs110969551,104 (1369L)A>C0.360.090.18
    rs114666571,417 (1473T)T>C0.020.360.22
    rs41290092,332 (1775V)A>G0.170.250.34
    TNF-αrs1799724G1−857C>T0.070.990.99
    rs1800750G1−376G>A0.010.720.81
    rs3093662G1-IVS1 −122A>G0.040.960.87
    rs361525G2−238G>A0.030.990.99
    rs3093664G2-IVS3 +51A>G0.070.560.79
    rs3093665G3-EX4 +499A>C0.010.440.29
    rs1800629TNFa −308G>A0.180.110.12
    rs769178G4-3′ +1402G>T0.070.990.99
    rs1800630G5−863C>A0.170.940.76
    • NOTE: HRs (99% CIs) are shown in Supplementary Table 1.

    • Abbreviations: LRT, likelihood ratio test.

    • ↵* From a Cox proportional hazards model of the codominant genotype when the frequency of rare heterozygotes >0.05 and from a dominant genotype otherwise.

    • ↵† Controlling for age and geographic location.

    • ↵‡ Controlling for age, geographic location, and indicator variables for curative and hormonal treatment.

    • ↵§ HR (99% CI) for GT/TT versus GG: 0.54 (0.34, 0.87).

    • ↵∥ HR (99% CI) for TC versus TT: 1.57 (1.02, 2.41); CC versus TT: 1.02 (0.57, 1.84).

Additional Files

  • Tables
  • Supplementary Data, Stark, et al.

    Files in this Data Supplement:

    • Supplementary Tables 1-2
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 18 (6)
June 2009
Volume 18, Issue 6
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality
Jennifer R. Stark, Fredrik Wiklund, Henrik Grönberg, Fredrick Schumacher, Jennifer A. Sinnott, Meir J. Stampfer, Lorelei A. Mucci and Peter Kraft
Cancer Epidemiol Biomarkers Prev June 1 2009 (18) (6) 1859-1863; DOI: 10.1158/1055-9965.EPI-08-0981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality
Jennifer R. Stark, Fredrik Wiklund, Henrik Grönberg, Fredrick Schumacher, Jennifer A. Sinnott, Meir J. Stampfer, Lorelei A. Mucci and Peter Kraft
Cancer Epidemiol Biomarkers Prev June 1 2009 (18) (6) 1859-1863; DOI: 10.1158/1055-9965.EPI-08-0981
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Background
    • Materials and Methods
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement